Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214

Slides:

Advertisements

Similar presentations

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

Advertisements

A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion of Chemotherapy.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

CheckMate 025: A randomized, open-label, phase III study of nivolumab versus everolimus in advanced renal cell carcinoma Padmanee Sharma, Bernard Escudier,

The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal.

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) second interim analysis in.

1 First interim results of GIDEON: oncologists and non-oncologists appear to use sorafenib differently Alan P Venook, MD University of California, San.

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

ASCO 2009 BEVACIZUMAB IN METASTATIC RENAL CELL CARCINOMA: An Update of the CALGB and AVOREN Trials Reviewed by: Dr. Daniel.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.

CCO Independent Conference Coverage

CCO Independent Conference Coverage

Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

CCO Independent Conference Highlights

Sérgio Barroso Department of Oncology

CCO Independent Conference Coverage

CCO Independent Conference Highlights

A cura di Filippo de Marinis

Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer

CCO Independent Conference Highlights

Pazopanib: the role in the treatment of mRCC

CCO Independent Conference Coverage

CCO Independent Conference Coverage

LUX-Lung 3 clinical trial

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer

CCO Independent Conference Coverage

NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Emerging Role of Nivolumab in Advanced Renal Cell Carcinoma

SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*

Presented By Luca Malorni at 2017 ASCO Annual Meeting

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Second-line Therapy and Beyond for Advanced Renal Cell Carcinoma

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO.

Final results of the phase III, randomised, double-blind AVOREN trial of first-line bevacizumab + interferon-a2a in metastatic renal cell carcinoma Escudier.

until tumour progression until tumour progression

Metastatic Renal Cell Carcinoma

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Intervista a Filippo de Marinis

1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.

Plot with best overall response and study duration.

Enrollment and Outcomes

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The.

1Kantarjian HM et al. Lancet Oncol 2011;12:

Nab-paclitaxel: lo stato dell’arte

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Caso Clínico Enrique Grande Head of Medical Oncology

Change in individual tolerability assessment between baseline and study completion. Change in individual tolerability assessment between baseline and study.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Definition of health states

Redefiniendo el Tratamiento del Cáncer Renal

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Sources of health outcomes data used in the SJLIFE study where severity grading criteria of long-term and late-onset health events were applied. Sources.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

(A) Survival curves according to clinical response.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214 Enrique Grande Head of Medical Oncology Director of Clinical Research

Disclosures Honoraria for ad boards and/or lectures: Pfizer, BMS, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, Celgene Research Grants: Pfizer, Astra Zeneca, MTEM/Threshold, Roche, IPSEN, Lexicon Leadership roles in medical societies: ENETS, GETNE and GETHI Stocks or ownership interest: None

ESMO 2019 Guidelines 1st Line mRCC Escudier B, et al. Ann Oncol 2019

Current European Association of Urology updated Guidelines Powles T, et al. Eur Urol 2017

CheckMate 214: Changing paradigms in mRCC Motzer RJ, et al. N Engl J Med 2018

Curti BD. N Engl J Med 2018

Curti BD. N Engl J Med 2018

CheckMate 214 Trial Design Motzer RJ, et al. N Engl J Med 2018

CheckMate 214: Baseline characteristics Motzer RJ, et al. N Engl J Med 2018

CheckMate 214: Overall Survival in the ITT (follow up 30m) Tannir N, et al. ASCO GU 2019

CheckMate 214: Overall Survival by IMDC Risk Tannir N, et al. ASCO GU 2019

CheckMate 214: Investigator-Assessed PFS ITT Patients Tannir N, et al. ASCO GU 2019

CheckMate 214: Investigator-Assessed PFS by IMDC risk Tannir N, et al. ASCO GU 2019

CheckMate 214: Time from randomization to subsequent systemic anticancer therapy initiation or death in the ITT population McDermott DF, et al. ASCO GU 2019

CheckMate 214: Time from randomization to subsequent systemic anticancer therapy initiation or death in IMDC favorable risk pts McDermott DF, et al. ASCO GU 2019

Treatment Free Survival health states and endpoints McDermott DF, et al. ASCO GU 2019

Treatment Free Survival in ITT patients who discontinued protocol therapy McDermott DF, et al. ASCO GU 2019

Treatment Free Survival in IMDC favorable-risk patients who discontinued protocol therapy McDermott DF, et al. ASCO GU 2019

TFS in IMDC Intermediate/Poor-Risk Patients Who Discontinued Protocol Therapy and Had CR/PR or SD McDermott DF, et al. Oral presentation at the 7th International Kidney Cancer Simposium. Miami 2018

CheckMate 214: Investigator-Assessed Response by RECIST v1.1 Tannir N, et al. ASCO GU 2019

CheckMate 214: Objective response rate by Age Motzer RJ, et al. N Engl J Med 2018

CheckMate 214: Duration of Response Rini BI, et al. Presented at the 17th International Kidney Cancer Symposium; November 2–3, 2018; Miami, FL, USA

CheckMate 214: Overall Survival Rini BI, et al. Presented at the 17th International Kidney Cancer Symposium; November 2–3, 2018; Miami, FL, USA

CheckMate 214 Trial: Treatment-related AEs ITT Motzer RJ, et al. N Engl J Med 2018

CheckMate 214 Trial: Time to onset of any-grade treatment-related select AEs in the NIVO+IPI arm Tannir N, et al. Presented at the 13th European International Kidney Cancer Symposium; April 27–28, 2018; Prague, Czech Republic

Treatment-Related AEs Over Time by Most Common System Organ Class (All Treated Patients) Tannir N, et al. ASCO GU 2019

Treatment-related Aes leading to discontinuation within 100 days of last dose in the NIVO+IPI arm Tannir N, et al. ASCO GU 2019

Total NIVO doses received in pts who discontinued due to treatment-related AEs in the NIVO+IPI arm Tannir N, et al. ASCO GU 2019

Best Overall Response per Investigator by AEs Tannir N, et al. ASCO GU 2019

Overall Survival by treatment-related AEs discontinuation Tannir N, et al. ASCO GU 2019

Cella D, et al. Lancet Oncol 2019

CheckMate 214: Patient-reported Outcomes (FKSI-19) Cella D, et al. Lancet Oncol 2019

CheckMate 214: Cost-effectiveness Analysis Wam XM, et al. JAMA Oncol 2019

egrande@mdanderson.es @drenriquegrande